CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 84 enrolled
Drug / intervention
Erlotinibdrug
Likely dose
Not stated in record
Key inclusion· 8
  • ✓Female gender
  • ✓Diagnosis of adenocarcinoma of the lung
  • ✓Stage IIIB or IV non-small cell lung cancer
  • ✓Non-smoker or former smoker (≤100 cigarettes lifetime or quit ≥1 year ago)
Key exclusion· 7
  • ✕Prior exposure to erlotinib (Tarceva)
  • ✕Prior chemotherapy regimen
  • ✕Uncontrolled CNS disease
  • ✕Difficulty swallowing

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00137839
NCT00137839Phase 2Completed
CompareCT.gov

A Phase II Study of Erlotinib (OSI-774); Tarceva in Women With Previously Untreated Advance Adenocarcinoma of the Lung

Pasi A. Janne, MD, PhD·interventional·Posted Aug 30, 2005·Updated Dec 17, 2019

In Brief

A Phase 2 clinical trial evaluating Erlotinib for Adenocarcinoma and Non-small Cell Lung Cancer. Completed, enrolled 84 participants across 3 sites.

Detailed Summary

The purpose of this trial is to figure out what effects (good or bad) the investigational drug agent called Tarceva (erlotinib; OSI-774) has on women with previously untreated adenocarcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma, Non-small Cell Lung Cancer
CountriesUnited States
CollaboratorsDana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Genentech, Inc.

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 30, 2005
Enrollment StartNov 1, 2004
Primary CompletionNov 1, 2008
Study CompletionJul 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 20.8 years ago

Interventions

Erlotinibdrug